Table 3.
Efficacy of bispecific antibodies arranged in descending order.
| Agent | ORR | CR/sCR | VGPR | PR |
|---|---|---|---|---|
| Cevostamab [35] | 100% | 63% | 31% | 6% |
| Teclistamab + Daratumumab + Lenalidomide [22] | C1: 100% C2: 81% |
NR | C1: 92% C2: NR |
NR |
| Teclistamab + Daratumumab [21] | 78% | 24% | 73% | NR |
| Talquetamab + Daratumumab [33] | 77% | 29% | 65% | NR |
| Talquetamab [32] | 73% | 29% | 58% | NR |
| RG6234 [34] | C1: 71% C2: 60% |
C1: 29% C2: 19% |
C1: 29% C2: 21% |
C1: 14% C2: 21% |
| Elranatamab [23] | 64% | 38% | 56% | NR |
| Teclistamab [20] | 64% | 30% | NR | NR |
| Elranatamab [24] | 61% | NR | NR | NR |
| ABBV-383 [29] | 57% | 29% | 14% | 14% |
| REGN5458 [30] | 52% | 38% | NR | NR |
| Teclistamab [19] | 40% | 20% | NR | NR |
| WVT078 [31] | 35% | 12% | NR | NR |
| Pacanalotamab (AMG-420) [27] | 31% | 21% | 5% | 5% |
| Pavuratamb (AMG-701) [26] | 25% | 7% | 9% | 9% |
NR—not recorded, ORR—overall response rate, CR/sCR—complete response/stringent complete response, VGPR—very good partial response, and PR—partial response.